Telligen, as part of CodeX and in partnership with multiple leading oncology professional societies, clinical leaders, payers and other partners, introduced their CodeX Quality Measures for Cancer use case to more than 100 CodeX stakeholders from various organizations. Interested payers, clinicians and technology companies learned how FHIR-based interoperability can drive substantial improvements around the most important challenges and opportunities in patient health. 

Digital oncology quality measure development has been constrained by an ecosystem of diverse and unstructured data and a lack of digitalized collections and oncology models to support interoperability. As a result, most of this data collection requires manual effort, resulting in significant burden. There is little opportunity to share this information across systems or organizations due to a lack of a standardized process.   

The CodeX Quality Measures for Cancer team intends to create a solution using Fast Healthcare Interoperability Resources (FHIR) and mCODE to enable a path to data collection with reduced burden, focusing efforts on collection of meaningful oncology quality measure data, such as: 

  • The VA initiatives 
  • The Advancing Cancer Care MVP (MIPS) 
  • Supporting the Federal Cancer Moonshot Initiative 

The clinical oncology subject matter expertise of the CodeX community, paired with the mCODE profiles and FHIR Implementation Guides, should allow for the authoring of these quality metrics and provide a proof of concept for measure developers. 

The use case is currently in the initial discovery phase. Learn more about CodeX efforts here: